Prevest Denpro FY26 PAT rises 12.9% to ₹2,049.05 lakh

Prevest Denpro reported a 12.9% increase in consolidated Profit After Tax (PAT) to ₹2,049.05 lakh for the financial year ended March 31, 2026, driven by robust revenue growth and operational efficiencies. The company’s Revenue from Operations rose by 13.9% to ₹7,180.85 lakh, while EBITDA increased by 13.3% to ₹2,962.11 lakh. On a standalone basis, the company achieved an EBITDA margin of 39.8%, an expansion of 80 basis points, underpinned by cost savings from import substitution and optimized capacity utilization at its 60,000 sq. ft. manufacturing facility.

Financial Performance

The strong top-line performance was complemented by margin expansion across profitability metrics. The Standalone PAT margin improved to 27.9%, up 80 basis points, while the Profit Before Tax (PBT) margin stood at 37.2%, an increase of 110 basis points. Sequential growth in the fourth quarter was particularly notable, with consolidated PBT growing by 21.2% and PAT by 23.3% over the third quarter, driven by strong year-end closures and effective leverage on fixed costs during peak volumes.

Consolidated Financials (FY 25-26 vs FY 24-25)

Particulars (INR Lakhs)	FY 25-26	FY 24-25	% Change
Revenue from Operations	7,180.85	6,302.81	+13.9%
EBITDA	2,962.11	2,615.30	+13.3%
Profit Before Tax (PBT)	2,761.23	2,424.97	+13.9%
Profit After Tax (PAT)	2,049.05	1,815.52	+12.9%

Operational Highlights

Prevest Denpro’s strategic focus on product innovation and global expansion yielded significant results during the year. The company rolled out the high-margin "Oradox" range and expanded its 3D printing resin portfolio. Import substitution of raw materials contributed to cost savings in procurement. Geographically, the company strengthened its presence through the establishment of Axiodent Inc. in the USA and Prevest Gulf LLC in the UAE, capitalizing on its footprint in over 90 countries.

Strategic Outlook

Looking ahead to FY27, Prevest Denpro plans to expand into new categories such as Digital Dentistry and Disinfectants to drive future growth. The company aims to strengthen its domestic presence in Tier I and Tier II markets while entering new international territories to increase exports. Continued investment in R&D and the development of indigenous raw materials are expected to support long-term competitiveness and sustainability.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-2.10%	-4.63%	-5.99%	-23.66%	-20.73%	+96.73%

Prevest Denpro Limited has rescheduled its earnings discussion for the quarter and financial year ended March 31, 2026, to June 29, 2026, at 3:00 PM IST. The meeting, previously cancelled due to unforeseen circumstances, will provide insights into the company's operational and financial performance for Q4 FY26. This intimation was submitted in compliance with Regulation 30(6) read with Part A of Schedule II of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

The conference call will feature key management personnel who will discuss the results. Mrs. Namrata Modi, WTD & CFO, will lead the discussion alongside Dr. Sai Kalyan, Director of Research & Academics. Other participants include Mr. Vaibhav Munjal, Chief Marketing Officer, and Mr. Vinay Jamwal, Financial Advisor.

Conference Call Details

Detail	Information
Date	June 29, 2026
Time	3:00 PM IST
Agenda	Q4 and FY26 Results Discussion

Access Information

Participants can join the call via the following numbers:

Primary Number: +91 22 7115 8084, +91 22 6280 1361
USA: 18667462133
UK: 08081011573
Singapore: 8001012045
Hong Kong: 800964448

The event is organized by Hem Securities Ltd. Interested participants must register for the call. For RSVP and inquiries, stakeholders may contact Mr. Ramadhin Rane at ramadhin.r@hemsecurities.com or Mr. Prabal Maheshwari at lpo.mumbai@hemsecurities.com .